Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up

Deda, Haluk; İnci, Melek; Kürekçi, Ahmet Emin; Sav, Aydın; Kayihan, K; Ozgun, Elmas; Ustünsoy, G E; Kocabay, S

doi:10.1080/14653240802549470

Cited by 167 publications

(102 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These confirms and reassure the previous findings by other groups about the safety of the IT infusion of SCs [52,53,[68][69][70]72,77].…”

Section: Safetysupporting

confidence: 82%

“…Our results support the safety of the method and add unique information about the effectiveness of autologous stem cells to treat ALS supporting previous reports that described safety, feasibility and in some cases stop of the functional declination [52,53,[68][69][70]72,77].…”

Section: Alsfrs-rsupporting

confidence: 75%

“…Furthermore, other models point-out that BM-MNCs infusion via IT [50] or IM [51] have major beneficial effects in ALS. Therefore, and together with safety profiles described by other authors infusing SCs IT in ALS and other diseases [52,53,[62][63][64][65][66][67][68][69][70][71][72]] the use of BM-MNCs via IT, IM and IV in humans with ALS is rational.…”

Section: Rationalementioning

confidence: 99%

See 2 more Smart Citations

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

“…These confirms and reassure the previous findings by other groups about the safety of the IT infusion of SCs [52,53,[68][69][70]72,77].…”

Section: Safetysupporting

confidence: 82%

Section: Alsfrs-rsupporting

confidence: 75%

Section: Rationalementioning

confidence: 99%

See 1 more Smart Citation

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

“…Finally, a study in Turkey assessed patients following various routes of bone marrow-derived MSC administration and indicated that the procedure was safe, and in some cases motor improvement was also reported. [79].…”

Section: Bone Marrow-derived Hematopoietic Progenitor Stem Cellsmentioning

confidence: 99%

Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis

2015

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease of the motor neurons without a known cure. Based on the possibility of cellular neuroprotection and early preclinical results, stem cells have gained widespread enthusiasm as a potential treatment strategy. Preclinical models demonstrate a protective role of engrafted stem cells and provided the basis for human trials carried out using various types of stem cells, as well as a range of cell delivery methods. To date, no trial has demonstrated a clear therapeutic benefit; however, results remain encouraging and are the basis for ongoing studies. In addition, stem cell technology continues to improve, and induced pluripotent stem cells may offer additional therapeutic options in the future. Improved disease models and clinical trials will be essential in order to validate stem cells as a beneficial therapy.

show abstract

“…Therefore some researchers have attempted stem-cell-based approaches for the treatment of ALS patients. Current clinical trials are based principally on two main transplantation strategies: the systemic [39,40] and the local approaches [22,[41][42][43][44][45][46]. Mesenchymal stem cell transplantation into the spinal cords of ALS patients has been described, and the authors reported this method as safe [41].…”

Section: Introductionmentioning

confidence: 99%

Increase of Pyramidal Tract Fractional Anisotropy on MRI after Stem Cell Transplantation in ALS Patients

HR¹,

Garza²

2014

J Neurol Neurophysiol

View full text Add to dashboard Cite

Background and Purpose: Amyotrophic lateral sclerosis (ALS) is characterized by the selective death of motor neurons. Cortical neuron loss is associated with axonal degeneration along specific white matter tracts. Fractional anisotropy (FA) determined by Magnetic Resonance (MR) might detect integrity or changes in brain white matter pathways. This study was aimed to analyze pyramidal tract changes in ALS patients submitted to stem cell transplantation into the frontal motor cortices.

show abstract

Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up

Cited by 167 publications

References 18 publications

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis

Increase of Pyramidal Tract Fractional Anisotropy on MRI after Stem Cell Transplantation in ALS Patients

Contact Info

Product

Resources

About